Význam zobrazení srdce pomocí magnetické rezonance v diagnostice hypertrofické kardiomyopatie
Část I

Czech version

Authors: Martin Pleva ^1,2; Júlia Borová ¹; Ilona Plevová ³; Jaroslav Januška ¹; Margita Belicová ⁴
Authors‘ workplace: Komplexní kardiovaskulární centrum Nemocnice Podlesí a. s., Třinec ¹; Vaskulární centrum Vítkovické nemocnice, a. s., Ostrava ²; Ústav ošetřovatelství a porodní asistence LF OU, Ostrava ³; I. interná klinika JLF UK a UNM, Martin, Slovenská republika ⁴
Published in: Vnitř Lék 2017; 63(3): 194-198
Category: Reviews

Overview

Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy in our population. The diagnosis of this disease is based on imaging methods, mainly echocardiography. Cardiac magnetic resonance offers more accurate and detailed information about the disease than echocardiography. Development of this method has become a standard part of the diagnostic algorithm. In the first part of review, the authors analyze the potential and significance of cardiac magnetic resonance in the diagnosis of hypertrophic cardiomyopathy.

Key words:
cardiac magnetic resonance – fibrosis – hypertrophic cardiomyopathy

Sources

1. Maron BJ, Ommen SR, Semsarian C et al. Hypertrophic cardiomyopathy. Present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014; 64(1): 83–99. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.05.003>.

2. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010; 121(3): 445–456. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.878579>. Erratum in Circulation 2010; 122(1): e7.

3. Elliott PM, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29(2): 270–276.

4. Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35(39): 2733–2779. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu284>.

5. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2012; 14: 13. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-14-13>.

6. Germans T, Nijveldt R, Brouwer WP et al. The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy. Neth Heart J 2010; 18(3): 135–143.

7. Rickers C, Wilke NM, Jerosch-Herold M et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112(6): 855–861.

8. Pleva M, Ouředníček P. MRI srdce. Praktické využití z pohledu kardiologa. Grada Publishing: Praha 2012. ISBN 978–80–247–3931–1.

9. Stewart GA, Foster J, Cowan M et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56(6): 2248–2253.

10. Olivotto I, Maron MS, Autore C et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52(7): 559–566. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.04.047>.

11. Maron MS, Maron BJ, Harrigan C et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54(3): 220–228. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.05.006>.

12. Maron MS, Olivotto I, Harrigan CJ et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011; 124(1): 40–47. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.985812>.

13. Kwon DH, Setser RM, Thamilarasan M et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2008; 94(10): 1295–1301.

14. Harrigan CJ, Appelbaum E, Maron BJ et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2008; 101(5): 668–673. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2007.10.032>.

15. Veselka J, Linhartová K, Zemánek D. Kardiomyopatie. Galén: Praha 2009. ISBN 978–80–7262–640–3.

16. To AC, Dhillon A, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2011; 4(10): 1123–1237. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2011.06.022>.

17. Moon JC, McKenna WJ. Myocardial crypts: a prephenotypic marker of hypertrophic cardiomyopathy? Circ Cardiovasc Imaging 2012; 5(4): 431–432. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.112.975888>.

18. Maron MS, Rowin EJ, Lin D et al. Prevalence and clinical profil of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2012; 5(4): 441–447. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.112.972760>.

19. Germans T, Wilde AAM, Dijkmans PA et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006; 48(12): 2518–2523.

20. Child N, Muhr T, Sammut E et al. Prevalence of myocardial crypts in a large retrospective cohort study by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014; 16: 66. Dostupné z DOI: <http://dx.doi.org/10.1186/s12968-014-0066-0>.

21. Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part I, MRI appearances. AJR Am J Roentgenol 2007; 189(6): 1335–1343.

22. Maron MS, Hauser TH, Dubrow E et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol 2007; 100(8): 1293–1298.

23. Maron MS. Contrast-enhanced CMR in HCM. What lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging 2013; 6(5): 597–599. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2012.10.028>.

24. Moravsky G, Ofek E, Rakowski H et al. Myocardial fibrosis in hypertrophic cardiomyopathy. Accurate reﬂection of histopathological findings by CMR. JACC Cardiovasc Imaging 2013; 6(5): 587–596. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2012.09.018>.

25. Noureldin RA, Liu S, Nacif MS et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14: 17. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-14-17>.

26. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51(14): 1369–1374. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.11.071>.

27. Ismail TF, Jabbour A, Gulati A et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratiﬁcation of hypertrophic cardiomyopathy. Heart 2014; 100(23): 1851–1858. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2013-305471>.

28. Olivotto I, Maron BJ, Appelbaum E et al. Olivotto I, Maron BJ, Appelbaum E et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010; 106(2): 261–267. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2010.03.020>.

29. Chan RH, Maron BJ, Olivotto I et al. Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2015; 17(Suppl 1): Q59. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-17-S1-Q59>.

30. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrofic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58(25): e212-e260. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.06.011>.